In This Article:
As European markets experience a boost in sentiment following the easing of trade tensions between the U.S. and China, major indices such as Germany’s DAX and France’s CAC 40 have posted notable gains. In this environment, identifying undervalued stocks becomes crucial for investors seeking opportunities that may offer potential value relative to their current market price amidst improved economic conditions.
Top 10 Undervalued Stocks Based On Cash Flows In Europe
Name | Current Price | Fair Value (Est) | Discount (Est) |
Lectra (ENXTPA:LSS) | €24.10 | €47.47 | 49.2% |
Absolent Air Care Group (OM:ABSO) | SEK218.00 | SEK417.99 | 47.8% |
Vestas Wind Systems (CPSE:VWS) | DKK110.30 | DKK214.43 | 48.6% |
Arcure (ENXTPA:ALCUR) | €4.765 | €9.20 | 48.2% |
Claranova (ENXTPA:CLA) | €2.84 | €5.48 | 48.2% |
MilDef Group (OM:MILDEF) | SEK229.00 | SEK437.52 | 47.7% |
illimity Bank (BIT:ILTY) | €3.684 | €7.28 | 49.4% |
3U Holding (XTRA:UUU) | €1.59 | €3.12 | 49.1% |
Expert.ai (BIT:EXAI) | €1.332 | €2.59 | 48.5% |
HBX Group International (BME:HBX) | €10.26 | €19.68 | 47.9% |
Underneath we present a selection of stocks filtered out by our screen.
SNGN Romgaz
Overview: SNGN Romgaz SA is a Romanian company involved in the exploration, production, and supply of natural gas, with a market cap of RON22.66 billion.
Operations: The company's revenue segments include natural gas production and supply, generating RON5.23 billion, electricity production contributing RON1.24 billion, and storage services adding RON0.48 billion.
Estimated Discount To Fair Value: 46.8%
SNGN Romgaz is trading at RON5.88, significantly below its estimated fair value of RON11.04, indicating it may be undervalued based on cash flows. Despite slower revenue growth forecasts of 10.5% annually, earnings are expected to grow faster than the Romanian market at 12.8%. Recent quarterly results showed a decline in net income to RON950.98 million from RON1,245.33 million year-on-year, highlighting potential challenges despite its attractive valuation relative to peers and industry standards.
-
Our growth report here indicates SNGN Romgaz may be poised for an improving outlook.
-
Navigate through the intricacies of SNGN Romgaz with our comprehensive financial health report here.
Ambu
Overview: Ambu A/S is a medical technology company that develops, produces, and sells medical devices to hospitals, clinics, and rescue services globally, with a market cap of DKK28.02 billion.
Operations: The company generates revenue primarily from its Disposable Medical Products segment, which accounts for DKK5.83 billion.